Below you'll find a list of all posts that have been tagged as “Kyowa Hakko Kirin”
First Approved Treatment for XLH in Canada that Targets the Underlying Cause of this Rare, Hereditary, Lifelong Disease.
Borders-based specialty pharmaceutical company, Kyowa Kirin International plc (KKI), hosted Dr. Nobuo Hanai, President and Chief Executive Officer of KKI’s parent company, Kyowa Hakko Kirin Co. Ltd., at the company’s head office in Galashiels this week.
Spreng Thomson: Intelligent Creative Communications
+44(0)141 548 5191
info@sprengthomson.com
The Herald Building,
155 Albion Street,
Glasgow G1 1RU, UK
© 2019 Spreng Thomson Limited.
Registered in Scotland No. 173454
Client news: New website for @forthports showcases Group’s world class services. Read more here: bit.ly/2TJMWzl pic.twitter.com/vRpf…
